{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 (leucine-rich repeat protein kinase 2) is mutated in a significant number of Parkinson's disease patients... disruption of the interaction of LRRK2 with 14-3-3 may be linked to Parkinson's disease.",
          "judgment": "Yes",
          "reasoning": "The paper aims to link disruption of LRRK2's interaction with 14-3-3 to Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The assays used measure LRRK2 phosphorylation, 14-3-3 binding, and cellular localization. These assays model LRRK2 function and its interaction with other proteins, and how disruptions might lead to PD.",
          "judgment": "Yes",
          "reasoning": "The general class of assays (phosphorylation, binding, localization) are applicable to understanding LRRK2 function and its role in PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "We expressed full-length wild-type and mutant forms of LRRK2 with an N-terminal FLAG epitope tag in HEK-293 cells... Similar levels of LRRK2 forms were subjected to immunoblot analysis...",
          "judgment": "Yes",
          "reasoning": "The paper includes a wild-type control. Replicates were used (stated in figure legend: Assays were performed in duplicate, for three experiments...). Null control is not explicitly mentioned.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable, as there were no known benign or pathogenic variants used as controls.",
          "judgment": "No",
          "reasoning": "The paper doesn't mention using any known pathogenic or benign variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Data are the average for duplicate experiments that were repeated four separate times with similar results.",
          "judgment": "No",
          "reasoning": "The paper doesn't provide any specific statistical analysis (p-values, confidence intervals, effect sizes, or OddsPath calculations).",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Not directly applicable. The number of benign/pathogenic controls are not mentioned.",
          "judgment": "N/A",
          "reasoning": "Since no pathogenic or benign controls were explicitly used (or at least not described as such), we cannot apply this step.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The R1441C variant shows reduced Ser910/Ser935 phosphorylation and 14-3-3 binding. The study includes a wild-type control and replicates. It reaches PS3_supporting due to the lack of variant controls and robust statistical analysis."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "G",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441G"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 (leucine-rich repeat protein kinase 2) is mutated in a significant number of Parkinson's disease patients... disruption of the interaction of LRRK2 with 14-3-3 may be linked to Parkinson's disease.",
          "judgment": "Yes",
          "reasoning": "The paper aims to link disruption of LRRK2's interaction with 14-3-3 to Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The assays used measure LRRK2 phosphorylation, 14-3-3 binding, and cellular localization. These assays model LRRK2 function and its interaction with other proteins, and how disruptions might lead to PD.",
          "judgment": "Yes",
          "reasoning": "The general class of assays (phosphorylation, binding, localization) are applicable to understanding LRRK2 function and its role in PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "We expressed full-length wild-type and mutant forms of LRRK2 with an N-terminal FLAG epitope tag in HEK-293 cells... Similar levels of LRRK2 forms were subjected to immunoblot analysis...",
          "judgment": "Yes",
          "reasoning": "The paper includes a wild-type control. Replicates were used (stated in figure legend: Assays were performed in duplicate, for three experiments...). Null control is not explicitly mentioned.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable, as there were no known benign or pathogenic variants used as controls.",
          "judgment": "No",
          "reasoning": "The paper doesn't mention using any known pathogenic or benign variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Data are the average for duplicate experiments that were repeated four separate times with similar results.",
          "judgment": "No",
          "reasoning": "The paper doesn't provide any specific statistical analysis (p-values, confidence intervals, effect sizes, or OddsPath calculations).",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Not directly applicable. The number of benign/pathogenic controls are not mentioned.",
          "judgment": "N/A",
          "reasoning": "Since no pathogenic or benign controls were explicitly used (or at least not described as such), we cannot apply this step.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The R1441G variant shows reduced Ser910/Ser935 phosphorylation and 14-3-3 binding. The study includes a wild-type control and replicates. It reaches PS3_supporting due to the lack of variant controls and robust statistical analysis."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "H",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441H"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 (leucine-rich repeat protein kinase 2) is mutated in a significant number of Parkinson's disease patients... disruption of the interaction of LRRK2 with 14-3-3 may be linked to Parkinson's disease.",
          "judgment": "Yes",
          "reasoning": "The paper aims to link disruption of LRRK2's interaction with 14-3-3 to Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The assays used measure LRRK2 phosphorylation, 14-3-3 binding, and cellular localization. These assays model LRRK2 function and its interaction with other proteins, and how disruptions might lead to PD.",
          "judgment": "Yes",
          "reasoning": "The general class of assays (phosphorylation, binding, localization) are applicable to understanding LRRK2 function and its role in PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "We expressed full-length wild-type and mutant forms of LRRK2 with an N-terminal FLAG epitope tag in HEK-293 cells... Similar levels of LRRK2 forms were subjected to immunoblot analysis...",
          "judgment": "Yes",
          "reasoning": "The paper includes a wild-type control. Replicates were used (stated in figure legend: Assays were performed in duplicate, for three experiments...). Null control is not explicitly mentioned.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable, as there were no known benign or pathogenic variants used as controls.",
          "judgment": "No",
          "reasoning": "The paper doesn't mention using any known pathogenic or benign variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Data are the average for duplicate experiments that were repeated four separate times with similar results.",
          "judgment": "No",
          "reasoning": "The paper doesn't provide any specific statistical analysis (p-values, confidence intervals, effect sizes, or OddsPath calculations).",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Not directly applicable. The number of benign/pathogenic controls are not mentioned.",
          "judgment": "N/A",
          "reasoning": "Since no pathogenic or benign controls were explicitly used (or at least not described as such), we cannot apply this step.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The R1441H variant shows reduced Ser910/Ser935 phosphorylation and 14-3-3 binding. The study includes a wild-type control and replicates. It reaches PS3_supporting due to the lack of variant controls and robust statistical analysis."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "Y",
          "alt": "C",
          "position": "1699"
        },
        "variant_string_id": "LRRK2 Y1699C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 (leucine-rich repeat protein kinase 2) is mutated in a significant number of Parkinson's disease patients... disruption of the interaction of LRRK2 with 14-3-3 may be linked to Parkinson's disease.",
          "judgment": "Yes",
          "reasoning": "The paper aims to link disruption of LRRK2's interaction with 14-3-3 to Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The assays used measure LRRK2 phosphorylation, 14-3-3 binding, and cellular localization. These assays model LRRK2 function and its interaction with other proteins, and how disruptions might lead to PD.",
          "judgment": "Yes",
          "reasoning": "The general class of assays (phosphorylation, binding, localization) are applicable to understanding LRRK2 function and its role in PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "We expressed full-length wild-type and mutant forms of LRRK2 with an N-terminal FLAG epitope tag in HEK-293 cells... Similar levels of LRRK2 forms were subjected to immunoblot analysis...",
          "judgment": "Yes",
          "reasoning": "The paper includes a wild-type control. Replicates were used (stated in figure legend: Assays were performed in duplicate, for three experiments...). Null control is not explicitly mentioned.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable, as there were no known benign or pathogenic variants used as controls.",
          "judgment": "No",
          "reasoning": "The paper doesn't mention using any known pathogenic or benign variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Data are the average for duplicate experiments that were repeated four separate times with similar results.",
          "judgment": "No",
          "reasoning": "The paper doesn't provide any specific statistical analysis (p-values, confidence intervals, effect sizes, or OddsPath calculations).",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Not directly applicable. The number of benign/pathogenic controls are not mentioned.",
          "judgment": "N/A",
          "reasoning": "Since no pathogenic or benign controls were explicitly used (or at least not described as such), we cannot apply this step.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The Y1699C variant shows reduced Ser910/Ser935 phosphorylation and 14-3-3 binding. The study includes a wild-type control and replicates. It reaches PS3_supporting due to the lack of variant controls and robust statistical analysis."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 (leucine-rich repeat protein kinase 2) is mutated in a significant number of Parkinson's disease patients... disruption of the interaction of LRRK2 with 14-3-3 may be linked to Parkinson's disease.",
          "judgment": "Yes",
          "reasoning": "The paper aims to link disruption of LRRK2's interaction with 14-3-3 to Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The assays used measure LRRK2 phosphorylation, 14-3-3 binding, and cellular localization. These assays model LRRK2 function and its interaction with other proteins, and how disruptions might lead to PD.",
          "judgment": "Yes",
          "reasoning": "The general class of assays (phosphorylation, binding, localization) are applicable to understanding LRRK2 function and its role in PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "We expressed full-length wild-type and mutant forms of LRRK2 with an N-terminal FLAG epitope tag in HEK-293 cells... Similar levels of LRRK2 forms were subjected to immunoblot analysis...",
          "judgment": "Yes",
          "reasoning": "The paper includes a wild-type control. Replicates were used (stated in figure legend: Assays were performed in duplicate, for three experiments...). Null control is not explicitly mentioned.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable, as there were no known benign or pathogenic variants used as controls.",
          "judgment": "No",
          "reasoning": "The paper doesn't mention using any known pathogenic or benign variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Data are the average for duplicate experiments that were repeated four separate times with similar results.",
          "judgment": "No",
          "reasoning": "The paper doesn't provide any specific statistical analysis (p-values, confidence intervals, effect sizes, or OddsPath calculations).",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Not directly applicable. The number of benign/pathogenic controls are not mentioned.",
          "judgment": "N/A",
          "reasoning": "Since no pathogenic or benign controls were explicitly used (or at least not described as such), we cannot apply this step.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The I2020T variant shows reduced Ser910/Ser935 phosphorylation and 14-3-3 binding. The study includes a wild-type control and replicates. It reaches PS3_supporting due to the lack of variant controls and robust statistical analysis."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 (leucine-rich repeat protein kinase 2) is mutated in a significant number of Parkinson's disease patients... disruption of the interaction of LRRK2 with 14-3-3 may be linked to Parkinson's disease.",
          "judgment": "Yes",
          "reasoning": "The paper aims to link disruption of LRRK2's interaction with 14-3-3 to Parkinson's disease. Also, 'the most frequent mutation, comprising an amino acid substitution of the highly conserved Gly2019 located within the subdomain VII-DFG motif of the kinase domain, enhances protein kinase activity approx. 2-fold [8-10]' defines the mechanism.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The assays used measure LRRK2 phosphorylation, 14-3-3 binding, and cellular localization, as well as protein kinase activity. These assays model LRRK2 function and its interaction with other proteins, and how disruptions/enhancements might lead to PD.",
          "judgment": "Yes",
          "reasoning": "The general class of assays (phosphorylation, binding, localization and kinase activity) are applicable to understanding LRRK2 function and its role in PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "We expressed full-length wild-type and mutant forms of LRRK2 with an N-terminal FLAG epitope tag in HEK-293 cells... Similar levels of LRRK2 forms were subjected to immunoblot analysis...",
          "judgment": "Yes",
          "reasoning": "The paper includes a wild-type control. Replicates were used (stated in figure legend: Assays were performed in duplicate, for three experiments...). Null control is not explicitly mentioned.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable, as there were no known benign or pathogenic variants used as controls.",
          "judgment": "No",
          "reasoning": "The paper doesn't mention using any known pathogenic or benign variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Data are the average for duplicate experiments that were repeated four separate times with similar results.",
          "judgment": "No",
          "reasoning": "The paper doesn't provide any specific statistical analysis (p-values, confidence intervals, effect sizes, or OddsPath calculations).",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Not directly applicable. The number of benign/pathogenic controls are not mentioned.",
          "judgment": "N/A",
          "reasoning": "Since no pathogenic or benign controls were explicitly used (or at least not described as such), we cannot apply this step.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The G2019S variant displayed increased protein kinase activity (~3-fold). The study includes a wild-type control and replicates. It reaches PS3_supporting due to the lack of variant controls and robust statistical analysis."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "H",
          "position": "1728"
        },
        "variant_string_id": "LRRK2 R1728H"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 (leucine-rich repeat protein kinase 2) is mutated in a significant number of Parkinson's disease patients... disruption of the interaction of LRRK2 with 14-3-3 may be linked to Parkinson's disease.",
          "judgment": "Yes",
          "reasoning": "The paper aims to link disruption of LRRK2's interaction with 14-3-3 to Parkinson's disease, as well as increased kinase activity is implicated in some pathogenic variants.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The assays used measure LRRK2 phosphorylation, 14-3-3 binding, and cellular localization, as well as protein kinase activity. These assays model LRRK2 function and its interaction with other proteins, and how disruptions/enhancements might lead to PD.",
          "judgment": "Yes",
          "reasoning": "The general class of assays (phosphorylation, binding, localization and kinase activity) are applicable to understanding LRRK2 function and its role in PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "We expressed full-length wild-type and mutant forms of LRRK2 with an N-terminal FLAG epitope tag in HEK-293 cells... Similar levels of LRRK2 forms were subjected to immunoblot analysis...",
          "judgment": "Yes",
          "reasoning": "The paper includes a wild-type control. Replicates were used (stated in figure legend: Assays were performed in duplicate, for three experiments...). Null control is not explicitly mentioned.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable, as there were no known benign or pathogenic variants used as controls.",
          "judgment": "No",
          "reasoning": "The paper doesn't mention using any known pathogenic or benign variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Data are the average for duplicate experiments that were repeated four separate times with similar results.",
          "judgment": "No",
          "reasoning": "The paper doesn't provide any specific statistical analysis (p-values, confidence intervals, effect sizes, or OddsPath calculations).",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Not directly applicable. The number of benign/pathogenic controls are not mentioned.",
          "judgment": "N/A",
          "reasoning": "Since no pathogenic or benign controls were explicitly used (or at least not described as such), we cannot apply this step.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The R1728H variant displayed elevated protein kinase activity (~2-fold). The study includes a wild-type control and replicates. It reaches PS3_supporting due to the lack of variant controls and robust statistical analysis."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "T",
          "alt": "S",
          "position": "2031"
        },
        "variant_string_id": "LRRK2 T2031S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 (leucine-rich repeat protein kinase 2) is mutated in a significant number of Parkinson's disease patients... disruption of the interaction of LRRK2 with 14-3-3 may be linked to Parkinson's disease, as well as increased kinase activity is implicated in some pathogenic variants.",
          "judgment": "Yes",
          "reasoning": "The paper aims to link disruption of LRRK2's interaction with 14-3-3 to Parkinson's disease, as well as increased kinase activity is implicated in some pathogenic variants.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The assays used measure LRRK2 phosphorylation, 14-3-3 binding, and cellular localization, as well as protein kinase activity. These assays model LRRK2 function and its interaction with other proteins, and how disruptions/enhancements might lead to PD.",
          "judgment": "Yes",
          "reasoning": "The general class of assays (phosphorylation, binding, localization and kinase activity) are applicable to understanding LRRK2 function and its role in PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "We expressed full-length wild-type and mutant forms of LRRK2 with an N-terminal FLAG epitope tag in HEK-293 cells... Similar levels of LRRK2 forms were subjected to immunoblot analysis...",
          "judgment": "Yes",
          "reasoning": "The paper includes a wild-type control. Replicates were used (stated in figure legend: Assays were performed in duplicate, for three experiments...). Null control is not explicitly mentioned.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable, as there were no known benign or pathogenic variants used as controls.",
          "judgment": "No",
          "reasoning": "The paper doesn't mention using any known pathogenic or benign variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Data are the average for duplicate experiments that were repeated four separate times with similar results.",
          "judgment": "No",
          "reasoning": "The paper doesn't provide any specific statistical analysis (p-values, confidence intervals, effect sizes, or OddsPath calculations).",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Not directly applicable. The number of benign/pathogenic controls are not mentioned.",
          "judgment": "N/A",
          "reasoning": "Since no pathogenic or benign controls were explicitly used (or at least not described as such), we cannot apply this step.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The T2031S variant displayed elevated protein kinase activity (~4-fold). The study includes a wild-type control and replicates. It reaches PS3_supporting due to the lack of variant controls and robust statistical analysis."
    }
  ]
}
